帕金森病人血清分化型胚胎软骨表达基因1和肝X受体β水平的相关性研究
The levels of DEC1 and LXR β in Parkinson's disease and its correlation
-
摘要: 目的:探讨帕金森病(PD)病人血清中分化型胚胎软骨表达基因1(DEC1)和肝X受体β(LXRβ)水平及二者相关性。方法:选择PD病人50例(PD组),选择同期健康人群50名为对照(对照组)。检测2组受试者血清DEC1、LXRβ水平。结果:PD组血清DEC1水平明显高于对照组(P<0.01),LXRβ水平明显低于对照组(P<0.01)。不同性别的PD病人DEC1和LXRβ水平差异均无统计学意义(P>0.05);年龄≥ 60岁PD病人的LXRβ水平低于<60岁者(P<0.05);有认知功能障碍的PD病人DEC1和LXRβ水平分别明显高于和低于无认知障碍者(P<0.01);随病情分期加重,PD病人的DEC1水平逐渐升高,LXRβ水平逐渐降低(P<0.05~P<0.01)。PD病人血清DEC1水平与LXRβ水平呈负相关关系(r=-0.326,P<0.05)。结论:PD病人血清DEC1与LXRβ水平呈负相关关系,二者与PD的发病及病情进展有关。
-
关键词:
- 帕金森病 /
- 分化型胚胎软骨表达基因1 /
- 肝X受体β /
- 认知功能
Abstract: Objective:To explore the serum levels of differentiated embryonic chondrocyte expression gene 1(DEC1) and liver X receptor β(LXRβ) in Parkinson's disease(PD),and its correlation.Methods:Fifty PD patients and 50 healthy people were divided into the PD group and control group,respectively.The serum levels of DEC1 and LXRβ in two groups were tested.Results:The serum levels of DEC1 and LXRβ in PD group were significantly higher and lower than that in control group,respectively(P<0.01).The differences of serum levels of DEC1 and LXRβ between different genders of PD group were not statistically significant(P>0.05).The serum level of LXRβ in more than or equal to 60 years old PD patients was lower than that in less than 60 years old PD patients(P<0.05).The serum levels of DEC1 and LXRβ in PD patients with cognitive dysfunction were significantly higher and lower than those in PD patients without cognitive dysfunction,respectively(P<0.01).With the deterioration of PD patients,the serum levels of DEC1 and LXRβ gradually increased and decreased,respectively(P<0.05 to P<0.01).The serum level of DEC1 was negatively correlated with the level of LXRβ in PD patients(r=-0.326,P<0.05).Conclusions:The serum level of DEC1 is negatively correlated with the level of LXRβ in PD patients,which may be involved in the onset and progression of PD. -
[1] 范文慧,马驰,潘玉君,等.帕金森病的神经保护治疗[J].国际免疫学杂志,2015,38(4):383. [2] 李振光,于占彩,于成勇,等.早期帕金森病病人非运动症状的临床表现[J].中华神经科杂志,2015,48(8):672. [3] MANCINI F,COMI C,OGGIONI GD,et al.Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens[J].Parkinsonism Relat Disord,2014,20(1):27. [4] RAHNE KE,TAGESSON C,NYHOLM D.Motor fluctuations and Helicobacter pylori in Parkinson's disease[J].J Neurol,2013,260(12):2974. [5] DORSZEWSKA J,PRENDECKI M,LIANERI M,et al.Molecular fffects of L-dopa therapy in parkinson's disease[J].Curr Genomics,2014,15(1):11. [6] ATAIE A,ATAEE R,MANSOURY Z,et al.Homocysteine intracerebroventricular injection induces apoptosis in the Substantia nigra cells and Parkinson's disease likebehavior in Rats[J].Int J Mol Cell Med,2013,2(2):80. [7] 中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南(第三版)[J].中华神经科杂志,2014,47(6):428. [8] 陈立英,姜晔.瘦素对帕金森病病人神经功能的影响[J].中国生化药物杂志,2015,35(8):152. [9] SANTIAGO JA,SCHERZER CR,POTASHKIN JA.Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease[J].PLoS One,2014,9(10):e109042. [10] SEINO H,WU Y,MOROHASHI S,et al.Basic helix-loop-helix transcription factor DEC1 regulates the cisplatin-induced apoptotic pathway of human esophageal cancer cells[J].Biomed Res,2015,36(2):89. [11] SAPKOTA S,GEE M,SABINO J,et al.Association of homocysteine with ventricular dilatation and brain atrophy in Parkinson's disease[J].Mov Disord,2014,29(3):368. [12] SATO F,MURAGAKI Y,ZHANG Y.DEC1 negatively regulates AMPK activity via LKB1[J].Biochem Biophys Res Commun,2015,467(4):711. [13] NOMURA S,ENDO-UMEDA K,AOYAMA A,et al.Styrylphenylphthalimides as novel transrepression-selective liver X receptor (LXR) modulators[J].ACS Med Chem Lett,2015,6(8):902. [14] NIAN S,GAN X,TAN X,et al.Discovery and synthesis of a novel series of liver X receptor antagonists[J].Chem Pharm Bull (Tokyo),2015,63(8):628. [15] VALLELUNGA A,PEGORARO V,PILLERI M,et al.The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease[J].Neurol Sci,2014,35(1):73.
计量
- 文章访问数: 3382
- HTML全文浏览量: 426
- PDF下载量: 65
- 被引次数: 0